Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 4

Androgen Effects on the Reproductive Neuroendocrine Axis, 2025 Version

University of California, San Diego · with National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · NCT07092527

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–35 · Women only
Healthy volunteers
Accepted
Study type
Interventional · Phase 4
Target enrollment
80
US sites recruiting
1
Study start
December 5, 2025
Record last updated
January 15, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This research study investigates whether male-level exogenous androgens inhibit the reproductive neuroendocrine axis in otherwise healthy (non-PCOS) females.

Being studied: Testosterone Cypionate 50 milligrams per millileter (mg/mL) Injectable Solution

Conditions: Transgenderism; Reproductive Issues

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria: Transgender/Non-binary Group, Initiating Testosterone Group

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Aged 18-35
  • Plan to initiate testosterone therapy
  • History of regular menstrual cycles (every 24-35 days) at baseline, before beginning TRT

Inclusion Criteria: Cisgender Female Group

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Aged 18-35
  • Having regular menstrual cycles (every 24-35 days)

Exclusion Criteria: All

  • Pregnant
  • Incarcerated
  • Known cognitive impairment or institutionalized
  • Hemoglobin less than 11 gm/dl at screening evaluation
  • Weight less than 110 pounds
  • BMI \<18 or >35
  • Current endocrine disease- including untreated thyroid abnormalities, pituitary or adrenal disease, polycystic ovary syndrome, or androgen producing tumor
  • Current or recent pregnancy within two months of study enrollment
  • Current or recent breast feeding within two months of study enrollment
  • Diabetes, or renal, liver, or heart disease
  • History of oophorectomy or hysterectomy
  • History of radiation or surgery involving brain structures and/or pelvis/pelvic organs
  • Currently taking any medications that may affect their reproductive hormones, such as contraceptive medications, androgens, estrogens, progestins, gonadotropin-releasing hormone (GnRH) antagonists, insulinomimetics, and metformin.
  • History of prior testosterone therapy

Recruiting US locations

  • University of California, San Diego

    San Diego, CA 92037

    Site contact: Antoni Duleba, MD · 619-804-4765 · aduleba@health.ucsd.edu

Study contacts (from the official record)

  • Antoni Duleba, MD · 619-804-4765 · aduleba@health.ucsd.edu
  • Marisa Hildebrand, MPH · 619-804-4765 · mchildeb@health.ucsd.edu
All healthy volunteers studies in California →
Androgen Effects on the Reproductive Neuroendocrine Axis, 2025 Version (NCT07092527) | Bored Studies